- Report
- February 2025
- 200 Pages
Global
From €3978EUR$4,490USD£3,442GBP
- Report
- January 2025
- 175 Pages
Global
From €3978EUR$4,490USD£3,442GBP
- Report
- August 2025
- 244 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 378 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 172 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 336 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 390 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 485 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 573 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 474 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 279 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 278 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 220 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 171 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 578 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 475 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 172 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 563 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 372 Pages
Global
From €5183EUR$5,850USD£4,484GBP
- Report
- August 2025
- 184 Pages
Global
From €5183EUR$5,850USD£4,484GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more